Clinical studies on insulin lispro

Drugs of Today

Volumn 34, Issue SUPPL. C, 1998, Pages 37-50

  Anderson Jr , James H ^a   Koivisto, Veikko A ^b  

^a ELI LILLY AND COMPANY   (United States)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE; CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN INSULIN; HUMULIN U; INSULIN ANTIBODY; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

BODY WEIGHT; CLINICAL TRIAL; DIABETES MELLITUS; DRUG ABSORPTION; EXERCISE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; IMMUNOGENICITY; INSULIN RESISTANCE; META ANALYSIS; POSTPRANDIAL STATE; QUALITY OF LIFE; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031838586     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Chance, R.E., Frank, B.H., Radziuk, J.M., DiMarchi, R.D. Discovery and development of insulin lispro. Drugs Today 1998, 34 (Suppl. C): 1-9.
2. Howey, D.C., Bowsher, R.R., Brunelle, R.L., Woodworth, J.R. [Lys(B28), Pro(B29)]-human insulin: A rapidly absorbed analogue of human insulin. Diabetes 1994, 43: 396-402.
3. Howey, D.C., Bowsher, R.R., Brunelle, R.L. et al. [Lys(B28). Pro(B29)]-human insulin: Effect of injection time on post-prandial glycemia. Clin Pharmacol Ther 1995, 58: 459-69.
4. Lean, M.E.J., Ng, L.L., Tennison, B.R. Interval between insulin injection and eating in relation to blood glucose control in adult diabetics. Br Med J 1985, 290: 105-8.
5. Jørgensen, L.N., Nielsen, F.S. Timing of pre-meal insulins in diabetic patients on a multiple daily injection regimen. A questionnaire study. Diabetologia 1990, 33: A116.
6. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 1995, 18 (Suppl. 1): 8-15.
7. Llewelyn, J., Slieker, L.J., Zimmerman, J.L. Preclinical studies on insulin lispro. Drugs Today 1998, 34 (Suppl. C): 11-21.
8. Heinemann, L., Woodworth, J. Pharmacokinetics and glucodynamics of insulin lispro. Drugs Today 1998, 34 (Suppl. C): 23-36.
9. Barnett, A.H., Owens, D.R. Insulin analogues. Lancet 1997, 349: 47-51.
10. Campbell, R.K., Campbell, L.K., White, J.R. Insulin lispro: Its role in the treatment of diabetes mellitus. Ann Pharmacother 1996, 30: 1263-71.
11. Holleman, F., Hoekstra, J.B.L. Insulin lispro. New Engl J Med 1997, 337 (3): 176-83.
12. Anderson, J.H. Jr., Brunelle, R.L., Koivisto, V.A. et al. Reduction of post-prandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Diabetes 1997, 46: 265-70.
13. Andersen, J.H. Jr., Brunelle, R.L., Keohane, P. et al. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Arch Int Med 1997, 157: 1249-55.
14. Anderson, J.H. Jr., Brunelle, R.L., Koivisto, V.A., Trautmann, M.E., Vignati, L., DiMarchi, R. Improved mealtime treatment of diabetes mellitus using an insulin analogue. Clin Ther 1997, 19: 62-72.
15. Dimitriadis, G.D., Gerich, J.E. Importance of timing of preprandial sub-cutaneous insulin administration in the management of diabetes mellitus. Diabetes Care 1983, 6: 374-7.
16. Vignati, L., Anderson, J.H., Iverson, P.W. Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulin-dependent or noninsulin-dependent diabetes mellitus. Clin Ther 1997, 19: 1408-21.
17. Heinemann, L., Heise, T., Wahl, L.C. et al. Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: Using the rapid acting insulin analogue Lys(B28), Pro(B29) human insulin. Diabetes Med 1996, 13: 625-9.
18. Zinman, B., Tildesley, H., Chiasson, J.- L., Tsui, E., Strack, T. Insulin lispro in CSII: Results of a double-blind crossover study. Diabetes 1997, 46: 440-3.
19. Schernthaner, G., Wein, W., Sandholzer, K., Equiluz-Bruck, S., Birkett, M. Postprandial insulin lispro: A new option in type-1 diabetic patients. Diabetes 1997, 46 (Suppl. 1): 98A.
20. Data on file, Eli Lilly and Company.
21. Holcombe, J., Zalani, S., Arora, V. et al. Insulin lispro (LP) results in less nocturnal hypoglycemia compared with regular human insulin in adolescents with type I diabetes. Diabetes 1997, 46 (Suppl. 1): 103A.
22. Holcombe, J., Zalani, S., Arora, V. et al. Patient preference for insulin lispro versus Humulin® in adolescents with type I diabetes. Diabetologia 1997, 40(Suppl. 1): A343.
23. Holcombe, J., Zalani, S., Arora, V. Comparative study of insulin lispro and regular insulin in 481 adolescents with type I diabetes. Diabetologia 1997, 40(Suppl. 1): A344.
24. Rutledge, K.S., Chase, H.P., Klingensmith, G.J., Walravens, P.A., Slover, R.H., Garg, S.K. Effectiveness of postprandial Humalog in toddlers with diabetes. Pediatrics 1997, 100: 968-72.
25. Woodworth, J., Howey, D., Lutz, S., Santa, P., Brady, P., Bowsher, R. [Lys(B28).Pro(B29)] human insulin (K): Dose-ranging versus Humulin R (H). Diabetologia 1993, 36 (Suppl. 1): A155.
26. Antsiferov, M., Woodworth, J.R., Mayarov, A., Ristic, S., Dedov, I. Lower within patient variability in postprandial glucose excursion with lispro insulin analog compared with regular insulin. Diabetes 1995, 44 (Suppl. 1): A214.
27. Koivisto, V.A., Felig, P. Alterations in insulin absorption and in blood glucose control associated with varying insulin injection sites in diabetic patients. Ann Intern Med 1980, 92: 59-61.
28. ter Braak, E.W., Woodworth, J.R., Bianchi, R. et al. Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin. Diabetes Care 1996, 19: 1437-40.
29. B29-human insulin analog and regular human insulin in the correction of incidental hyperglycemia. Diabetes Care 1996, 19: 1426-9.
30. Burge, M.R., Castillo, K.R., Schade, D.S. Meal composition is a determinant of lispro-induced hypoglycemia in IDDM. Diabetes Care 1997, 20: 152-5.
31. Brunelle, R.L., Llewelyn, J., Vignati, L., Anderson, J., Koivisto, V.A. Humalog reduces the incidence of severe hypoglycemia in IDDM patients. Diabetologia 1997, 40 (Suppl. 1): A352.
32. Torlone, E., Fanelli, C., Rambotti, A.M. et al. Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28). Pro(B29)] in IDDM. Diabetologia 1994, 37: 713-20.
33. Tuominen, J.A., Karonen, S.-L., Melamies, L., Bolli, G., Koivisto, V.A. Exercise-induced hypoglycaemia in ID-DM patients treated with a short-acting insulin analogue. Diabetologia 1995, 38: 106-11.
34. Worth, R., Home, P.D., Johnston, D.G. et al. Intensive attention improves glycaemic control in insulin-dependent diabetes without further advantage from home blood glucose monitoring: results of a controlled trial. Br Med J 1982, 285: 1233-40.
35. De Veciana, M., Major, C.A., Morgan, M.A. et al. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. New Engl J Med 1995, 333: 1237-41.
36. Chiasson, J.-L., Josse, R.G., Hunt, J.A. et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus: A multicenter controlled clinical trial. Ann Intern Med 1994, 121: 928-35.
37. Torlone, E., Pampanelli, S., Lalli, C. et al. Effects of the short-acting insulin analog [Lys(B28),Pro(B29)] on postprandial blood glucose control in IDDM. Diabetes Care 1996, 19: 945-52.
38. Ebeling, P., Jansson, P.-A, Smith, U., Lalli, C., Bolli, G.B., Koivisto, V.A. Strategies toward improved control during insulin lispro therapy in IDDM. Importance of basal insulin. Diabetes Care 1997, 20: 1287-9.
39. Ebeling, P., Jansson, P.-A., Smith, U. et al. Optimal combination of insulin lispro and basal insulin improves glycemic control in IDDM. Diabetologia 1997, 40 (Suppl. 1): A351.
40. The Diabetes Control and Complications Trial Research Group. The absence of a glycemic threshold for the development of long-term complications: The perspective of the Diabetes Control and Complications Trial. Diabetes 1996, 45: 1289-98.
41. Gale, E.A.M. Insulin lispro: The first insulin analogue to reach the market. Pract Diabetes Int 1996, 13: 122-4.
42. Fineberg, N.S., Fineberg, S.E., Anderson, J.H., Birkett, M.A., Gibson, R.G., Hufferd, S. Immunologic effects of insulin lispro [Lys(B28), Pro(B29)-human insulin] in IDDM and NIDDM patients previously treated with insulin. Diabetes 1996, 45: 1750-4.
43. Fineberg, S.E., Fineberg, N.S., Anderson, J.H., Birkett, M. Insulin immune response to lyspro human insulin therapy in insulin naive type 1 and type 2 patients. Diabetologia 1995, 38 (Suppl. 1): A4.
44. Lahtela, J.T., Knip, M., Paul, R., Antonen, J., Salmi, J. Severe antibody-mediated human insulin resistance. Successful treatment with the insulin analog lispro: A case report. Diabetes Care 1997, 20: 71-3.
45. Henrichs, H.R., Linger, H., Trautmann, M.E., Pfützner, A. Severe insulin resistance treated with insulin lispro. Lancet 1996, 348: 1248.
46. Kotsanos, J.G., Vignati, L., Huster, W. et al. Health-related quality-of-life results from multinational clinical trials of insulin lispro: Assessing benefits of a new diabetes therapy. Diabetes Care 1997, 20: 948-58.